Loading...

High-Performance Healthcare Materials And Sustainable Polymers Will Create Value

Published
02 Sep 24
Updated
18 Sep 25
AnalystConsensusTarget's Fair Value
US$43.25
25.8% undervalued intrinsic discount
18 Sep
US$32.10
Loading
1Y
-34.1%
7D
0.2%

Author's Valuation

US$43.2525.8% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on18 Sep 25
Fair value Increased 2.98%

Analysts have raised Avient’s price target to $43.25, citing increased confidence in the new CEO’s strategic focus on high-growth markets, anticipated organic growth, and recovery potential in cyclical end markets. Analyst Commentary Increased optimism due to the new CEO's strategic focus on high-growth platforms and markets.

Shared on08 May 25
Fair value Decreased 2.82%

Shared on30 Apr 25
Fair value Decreased 0.32%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on23 Apr 25
Fair value Decreased 4.68%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25
Fair value Decreased 7.60%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25
Fair value Increased 14%

AnalystConsensusTarget has decreased revenue growth from 3.7% to 3.3%.

Shared on02 Apr 25
Fair value Decreased 19%

Shared on26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25
Fair value Decreased 3.32%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on11 Mar 25
Fair value Increased 28%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.